Spots Global Cancer Trial Database for A Study of EDP1503 in Patients With Colorectal Cancer, Breast Cancer, and Checkpoint Inhibitor Relapsed Tumors
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: A Study of EDP1503 in Patients With Colorectal Cancer, Breast Cancer, and Checkpoint Inhibitor Relapsed Tumors
Official Title: A Phase I Open-label Study of EDP1503 Alone and in Combination With Pembrolizumab in Patients With Advanced Metastatic Colorectal Carcinoma, Triple-negative Breast Cancer, and Checkpoint Inhibitor Relapsed Tumors
Study ID: NCT03775850
Study Description
Brief Summary: This study is being conducted to assess the safety, tolerability, and efficacy of EDP1503 alone and in combination with pembrolizumab in patients with advanced metastatic colorectal carcinoma, triple-negative breast cancer, and checkpoint inhibitor relapsed tumors
Detailed Description: This will be a Phase I open-label study which will involve a 2-week monotherapy with EDP1503, following which the patients will be dosed with a combination of EDP1503 and pembrolizumab.
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Highlands Oncology Group, Rogers, Arkansas, United States
Florida Cancer Specialists, Sarasota, Florida, United States
Stephenson Cancer Center, Oklahoma City, Oklahoma, United States
Tennessee Oncology, PLLC, Chattanooga, Tennessee, United States
Tennessee Oncology, Nashville, Tennessee, United States
Centre de Recherche du CHUM, Montréal, Quebec, Canada
Jewish General Hospital, Montréal, Quebec, Canada
CHU de Québec - Université Laval, Québec, , Canada
Contact Details
Name: Johanna Bendell, MD
Affiliation: SCRI Development Innovations, LLC
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
